Wall Street Zen Upgrades IQVIA (NYSE:IQV) to Buy

IQVIA (NYSE:IQV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other analysts also recently weighed in on IQV. Mizuho lifted their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. BMO Capital Markets boosted their price target on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday. Royal Bank Of Canada upped their price target on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. increased their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Stock Up 0.0%

Shares of NYSE:IQV opened at $235.09 on Friday. The business’s 50 day moving average is $194.75 and its 200 day moving average is $186.82. The stock has a market cap of $38.70 billion, a P/E ratio of 29.17, a price-to-earnings-growth ratio of 1.99 and a beta of 1.18. IQVIA has a 52-week low of $154.50 and a 52-week high of $251.36. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the company posted $2.81 EPS. IQVIA’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA will post 11.61 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is owned by insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of the company. Boston Partners acquired a new stake in IQVIA in the third quarter worth about $676,698,000. Norges Bank acquired a new position in shares of IQVIA during the fourth quarter valued at about $497,445,000. Victory Capital Management Inc. raised its position in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares during the last quarter. Orbis Allan Gray Ltd raised its position in shares of IQVIA by 96.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after purchasing an additional 933,554 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.